The Valeda Lumithera device is one of the first treatments specifically designed to combine photobiomodulation (PBM) therapy with the treatment of dry macular degeneration (AMD). This innovative, non-invasive device uses light-based technology to target the underlying causes of AMD, providing a promising new approach for patients in the early and moderate stages of the disease.
How the Valeda Lumithera Device Works
The Valeda device emits light at specific wavelengths that are absorbed by the retina. This light energy stimulates cellular processes, encouraging the retina to clear the drusen deposits that contribute to vision loss. By enhancing the function of retinal pigment epithelium (RPE) cells and photoreceptor cells, the device helps maintain the health of the retina, slow the progression of AMD, and restore some vision.
Each treatment session with the Valeda device is quick and painless, lasting only a few minutes. The procedure is performed in-office, making it convenient for patients who need regular therapy. While not a cure, clinical trials have shown that the Valeda device can significantly improve both visual acuity and contrast sensitivity, helping patients regain some of their lost vision and improve their quality of life.
Clinical Benefits and Results
Research and clinical trials have demonstrated that PBM therapy, as delivered by the Valeda Lumithera device, can reduce drusen buildup, improve retinal function, and restore vision. Patients who have undergone treatment with the Valeda device have reported clearer vision and better ability to navigate low-light environments, which significantly improves their ability to carry out everyday tasks such as reading and driving.
The Future of AMD Treatment
The introduction of the Valeda Lumithera device represents a major step forward in the treatment of dry AMD. By utilizing PBM therapy, this device directly addresses one of the root causes of vision loss in AMD—the buildup of drusen—offering patients a non-invasive, highly effective option for managing the disease. While AMD remains a challenging condition, therapies like the Valeda Lumithera device provide new hope for patients who may otherwise have limited options.
Burman Zuckerbrod Ophthalmology is proud to be one of the first practices in Michigan to offer this groundbreaking therapy, and we look forward to continuing to provide innovative solutions to help our patients fight AMD.